Cladribine Combined with Low-Dose Cytarabine as Frontline Treatment for Unfit Elderly Acute Myeloid Leukemia Patients: Results from a Prospective Multicenter Study of Polish Adult Leukemia Group (PALG)Bożena Katarzyna Budziszewska, Ewa Lech‐Marańda, Marek Hus et al.|Cancers|2021Cited by 11
Early induction intensification with cladribine, cytarabine, and mitoxantrone (CLAM) in AML patients treated with the DAC induction regimen: a prospective, non-randomized, phase II study of the Polish Adult Leukemia Group (PALG)Agnieszka Pluta, Agnieszka Wierzbowska, Tadeusz Robak et al.|Leukemia & lymphoma/Leukemia and lymphoma|2019Cited by 3
Stratification Using ECOG, ADL and HCT-CI Scales, but Not CGA Enables Identifying Elderly AML Patients Fit for Intensive Chemotherapy - a Multicenter Study from Polish Adult Leukemia GroupBożena Katarzyna Budziszewska, Ewa Lech‐Marańda, Michał Łomiak et al.|Blood|2023Cited by 1
A compelling case for central pathology review of multiparameter flow cytometry measurable residual disease results in Acute Myeloid Leukemia (AML) clinical trials: Data from the PALG-AML1/2016 multicenter randomized studyAgnieszka Wierzbowska, Gail J. Roboz, Anna Czyż et al.|Blood|2025Cited by 1
P491: DAY 14 MEASURABLE RESIDUAL DISEASE ASSESSMENT PREDICTS TREATMENT OUTCOMES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH INTENSIVE CHEMOTHERAPY - RESULTS OF THE PALG-AML1/2016 STUDYAgnieszka Wierzbowska, Gail J. Roboz, Agnieszka Pluta et al.|HemaSphere|2023Cited by 0